Showing results (151-160 of 166) with videos related to
Sort By:
Pageof 17
The Journal of Cell Biology|May 1, 2002
Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradationKristina Lindsten, Femke M S de Vrij, Lisette G G C Verhoef, et al.Blood|July 31, 2010
A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapyChristopher P Fox, Tracey A Haigh, Graham S Taylor, et al.Journal of Virology|August 25, 2017
Asymptomatic Primary Infection with Epstein-Barr Virus: Observations on Young Adult CasesRachel J Abbott, Annette Pachnio, Isabela Pedroza-Pacheco, et al.Plos One|March 3, 2011
Thioredoxin 80-activated-monocytes (TAMs) inhibit the replication of intracellular pathogensXimena Cortes-Bratti, Eugénie Bassères, Fabiola Herrera-Rodriguez, et al.Plos Pathogens|August 20, 2016
Compartmentalization of Total and Virus-Specific Tissue-Resident Memory CD8+ T Cells in Human Lymphoid OrgansHeng Giap Woon, Asolina Braun, Jane Li, et al.Cancer Research|January 26, 2013
Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patientsEdwin P Hui, Graham S Taylor, Hui Jia, et al.Journal of Virology|March 20, 2015
Genome diversity of Epstein-Barr virus from multiple tumor types and normal infectionAnne L Palser, Nicholas E Grayson, Robert E White, et al.Plos Pathogens|March 28, 2015
Early virological and immunological events in asymptomatic Epstein-Barr virus infection in African childrenShamanthi Jayasooriya, Thushan I de Silva, Jainaba Njie-jobe, et al.Plos Biology|November 10, 2011
Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAPUmaimainthan Palendira, Carol Low, Anna Chan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2014
A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancerGraham S Taylor, Hui Jia, Kevin Harrington, et al.Pageof 17